



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation, the Chinese original shall prevail.

2024 第一季度报告

The First Quarter Report in 2024

甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	8
三、季度财务报表 III Quarterly Financial Statements	12

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真实、准确、完整。

第一季度财务报表是否经审计

否

Important notes:

The Board of Directors, the Supervisory Committee and directors, supervisors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

The legal representative, chief accountant, and head of accounting department (accounting supervisor) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the first quarter financial statements are audited

No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Item	本报告期 Current reporting period	本报告期比上年同期增减 变动幅度(%) Change in the current reporting period over the same period of the previous year (%)	
营业收入 Operating income	560,334,209.70	0.42	
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	96,004,278.20	95.04	
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	17,169,319.18	-42.93	
经营活动产生的现金流量净额 Net cash flows from perating activities	81,288,354.73	不适用 N/A	
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.16	77.78	
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.16	77.78	
加权平均净资产收益率(%) Weighted average return on net assets (%)	0.89	0.38	
	本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增 减变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total assets	11,719,954,413.58	11,715,023,471.80	0.04
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company	10,842,590,528.90	10,742,506,022.92	0.93

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gains and losses

单位：元 币种：人民币
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period
非流动性资产处置损益，包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions	579,596.73
计入当期损益的政府补助，但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	2,069,931.77
除同公司正常经营业务相关的有效套期保值业务外，非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	87,766,570.01
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	1,943,773.17
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses	470,697.75
减：所得税影响额	Less: Amount affected by income tax	13,995,610.41
合计	Total	78,834,959.02

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为的非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses" and the amount of which is material, as well as items defined as non-recurring gains and losses in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses", the reasons shall be explained.

项目名称 Item	涉及金额 Amount	原因 Reason
递延收益的摊销 Amortization of deferred income	2,300,908.72	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称 Item	变动比例(%) Percentage of change (%)	主要原因 Main Reason
归属于上市公司股东的净利润 Net profit attributable to shareholders of listed companies	95.04	本报告期归属于上市公司股东的净利润同比增长 95.04%，主要系报告期内公司持有的证券投资公允价值变动收益增加所致。 Net profit attributable to shareholders of the listed company for the reporting period increased by 95.04% year-on-year, which was mainly attributable to the increase in gain from changes in the fair value of securities investments held by the Company during the reporting period.
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	-42.93	本报告期归属于上市公司股东的扣除非经常性损益的净利润同比下降42.93%，主要系报告期内研发费用同比增加所致。 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses for the reporting period decreased by 42.93% year-on-year, which was mainly attributable to the year-on-year increase in R&D expenses during the reporting period.
经营活动产生的现金流量净额 Net cash flows from operating activities	不适用 N/A	主要系报告期内销售商品、提供劳务收到的现金及收到的税费返还增加所致。 This was mainly due to the increase in cash received from sales of goods and services, and tax rebates received during the reporting period.
基本每股收益 Basic earnings per share	77.78	主要系本报告期归属于上市公司股东的净利润同比增加所致。 This was mainly due to the year-on-year increase in net profit attributable to shareholders of the listed company for the reporting period.
稀释每股收益 Diluted earnings per share	77.78	主要系本报告期归属于上市公司股东的净利润同比增加所致。 This was mainly due to the year-on-year increase in net profit attributable to shareholders of the listed company for the reporting period.

股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

(I) The total number of ordinary shareholders, the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholding

单位：股
Unit: Share

报告期末普通股股东总数	83,780	报告期末表决权恢复的优先股股东总数(如有)	无												
Total number of ordinary shareholders at the end of the current reporting period	83,780	Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)	None												
前10名股东持股情况(不含通过转融通出借股份)															
Shareholdings of top ten shareholders (excluding lending of shares through a swap)															
股东名称	Shareholder name	股东性质	Nature of shareholders	持股数量	Number of shares held	持股比例(%)	Shareholding ratio (%)	持有有限售条件股份数量	Number of restricted shares held	质押、标记或冻结情况	Status of shares pledged, tagged or frozen	股份状态	Share status	数量	Number
甘忠如	Zhongru Gan	境内自然人	Domestic natural person	205,643,757	205,643,757	34.61	34.61	28,508,550	28,508,550	质押	Pledged	无	无	63,260,000	63,260,000
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人	Domestic non-state-owned legal entity	47,494,437	47,494,437	7.99	7.99			无	None	无	无		
明华创新技术投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	境外法人	Overseas legal entity	22,154,087	22,154,087	3.73	3.73	15,875,800	15,875,800	无	None	无	无		
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited	其他	Other	7,253,096	7,253,096	1.22	1.22			无	None	无	无		
甘喜茹	Xiru Gan	境内自然人	Domestic natural person	6,223,276	6,223,276	1.05	1.05			无	None	无	无		
Vast Wintersweet Limited	Vast Wintersweet Limited	境外法人	Overseas legal entity	6,045,405	6,045,405	1.02	1.02	5,777,913	5,777,913	无	None	无	无		
中国银行股份有限公司-招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	其他	Other	4,626,700	4,626,700	0.78	0.78			无	None	无	无		
Hillhouse G&L Holdings (HK) Limited	Hillhouse G&L Holdings (HK) Limited	境外法人	Overseas legal entity	4,357,832	4,357,832	0.73	0.73	4,296,032	4,296,032	无	None	无	无		
STRONG LINK INTERNATIONAL LIMITED	STRONG LINK INTERNATIONAL LIMITED	国有法人	State-owned legal entity	4,256,033	4,256,033	0.72	0.72	4,256,033	4,256,033	无	None	无	无		
中国农业银行股份有限公司-鹏华医药科技股票型证券投资基金	Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Fund	其他	Other	3,091,600	3,091,600	0.52	0.52			无	None	无	无		

单位：股
Unit: Share

前10名无限售条件股东持股情况

Shareholdings of the top ten shareholders with unlimited trading conditions

股东名称	Shareholder name	持有无限售条件流通股的数量	股份种类	股份种类及数量
		Number of unlimited shares outstanding	Category	Category and Number of shares
				数量
				Number

甘忠如	Zhongru Gan	177,135,207	人民币普通股	RMB ordinary shares 177,135,207
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co.,Ltd	47,494,437	人民币普通股	RMB ordinary shares 47,494,437
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited	7,253,096	人民币普通股	RMB ordinary shares 7,253,096
明华创新技术投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	6,278,287	人民币普通股	RMB ordinary shares 6,278,287
甘喜茹	Xiru Gan	6,223,276	人民币普通股	RMB ordinary shares 6,223,276
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund	4,626,700	人民币普通股	RMB ordinary shares 4,626,700
中国农业银行股份有限公司－腾华医药科技股票型证券投资基金	Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Fund	3,091,600	人民币普通股	RMB ordinary shares 3,091,600
张加珍	Jiazhen Zhang	2,600,000	人民币普通股	RMB ordinary shares 2,600,000
招商银行股份有限公司－南方阿尔法混合型证券投资基金	China Merchants Bank Corporation - Southern Alpha Mixed Securities Investment Fund	2,465,834	人民币普通股	RMB ordinary shares 2,465,834
甘一如	Yiru Gan	2,215,637	人民币普通股	RMB ordinary shares 2,215,637

上述股东关系或一致行动的说明
Explanation of the above shareholders' affiliation or concerted action

公司控股股东、实际控制人甘忠如持有旭特宏达65.02%的股权；甘喜茹为甘忠如胞妹。除以上情况外，其他股东之间不存在关联关系或一致行动。
Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 65.02% of the shares of Beijing Xute Hongda Technology Co.,Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.

前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有)
Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)

上述股东中张加珍先生通过信用证券账户持有2,600,000股。
Among the above shareholders, Mr. Zhang Jiazhen holds 2.6 million shares through a credit securities account.

Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business

单位：股
Unit: Share

持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况

Participation of shareholders holding 5% or more of shares, the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business

持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况
 Participation of shareholders holding 5% or more of shares, the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business

股东名称
(全称)

Shareholder name (full name)

Shareholder name (full name)	期初普通账户、信用账户持股 General and credit account holdings at the beginning of the current period	期初转融通出借股份且尚未归还 Shares lent in the transfer and refinancing business and has not yet been returned at the beginning of the current period	期末普通账户、信用账户持股 General and credit account holdings at the end of the current period	期末转融通出借股份且尚未归还 Shares lent in the transfer and refinancing business and has not yet been returned at the end of the current period
	数量合计 Total quantity	数量合计 Total quantity	数量合计 Total quantity	数量合计 Total quantity
	比例 (%) Proportion (%)	比例 (%) Proportion (%)	比例 (%) Proportion (%)	比例 (%) Proportion (%)
中国银行股份有限公司－招商国 证生物医药指数分级证券投资基金	3,788,600	933,200	4,626,700	115,200
Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	0.64	0.16	0.78	0.02

季度财务报表

Quarterly Financial Statements



三、季度财务报表

III Quarterly Financial Statements

(一) 财务报表

(I) Financial statements

合并资产负债表
Consolidated statement of financial position2024年3月31日
March 31, 2024编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年3月31日 March 31, 2024	2023年12月31日 December 31, 2023
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	2,552,990,893.78	2,442,708,603.20
交易性金融资产	Financial assets held for trading	2,346,980,905.99	2,410,429,796.82
应收账款	Accounts receivable	269,599,231.21	383,735,270.90
应收款项融资	Financing receivables	18,561,967.25	1,634,782.89
预付款项	Prepayments	59,366,039.72	40,979,491.54
其他应收款	Other receivables	3,602,947.45	3,491,907.62
存货	Inventories	932,042,171.36	860,506,306.14
一年内到期的非流动资产	Non-current assets due within one year		
其他流动资产	Other current assets	31,883,590.65	32,263,551.43
流动资产合计	Total current assets	6,215,027,747.41	6,175,749,710.54
非流动资产:	Non-current Assets:		
债权投资	Debt investment	307,122,916.67	304,658,333.33
其他非流动金融资产	Other non-current financial assets	30,000,000.00	30,000,000.00
固定资产	Fixed assets	1,851,745,745.49	1,872,067,763.13
在建工程	Construction in progress	2,024,005,518.27	2,006,961,148.27
使用权资产	Right-of-use assets	4,475,734.51	6,592,364.52
无形资产	Intangible assets	271,278,567.88	278,082,595.92
开发支出	Development expenditures	818,633,186.96	813,105,292.99
长期待摊费用	Long-term deferred expenses	8,426,265.99	8,868,054.70
递延所得税资产	Deferred tax assets	152,239,174.14	168,953,020.84
其他非流动资产	Other non-current assets	36,999,556.26	49,985,187.56
非流动资产合计	Total non-current assets	5,504,926,666.17	5,539,273,761.26
资产总计	Total assets	11,719,954,413.58	11,715,023,471.80
流动负债:	Current Liabilities		
应付账款	Accounts payable	107,433,009.23	105,541,739.99
合同负债	Contract liabilities	32,639,152.15	52,991,852.39
应付职工薪酬	Payroll and employee benefits payable	151,941,854.52	139,761,214.89

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

项目	Item	2024年3月31日 March 31, 2024	2023年12月31日 December 31, 2023
应交税费	Taxes payable	10,206,577.59	16,910,777.27
其他应付款	Other payables	377,540,224.77	454,009,437.80
一年内到期的非流动负债	Non-current liabilities due within one year	2,292,334.37	3,958,443.73
其他流动负债	Other current liabilities	297,868.18	275,580.81
流动负债合计	Total current liabilities	682,351,020.81	773,449,046.88
非流动负债:	Non-current Liabilities:		
租赁负债	Lease liabilities	3,909,110.41	5,447,249.65
长期应付款	Long-term payable	13,778,661.53	13,995,107.23
预计负债	Provisions		
递延收益	Deferred income	177,324,731.68	179,625,640.40
递延所得税负债	Deferred tax liabilities		
其他非流动负债	Other non-current liabilities		
非流动负债合计	Total non-current liabilities	195,012,503.62	199,067,997.28
负债合计	Total liabilities	877,363,524.43	972,517,044.16
所有者权益(或股东权益):	Owners' (or Shareholders') equity:		
实收资本(或股本)	Paid-in capital (or share capital)	594,161,750.00	594,161,750.00
其他权益工具	Other equity instruments		
资本公积	Capital reserve	3,354,945,052.71	3,350,753,839.87
减: 库存股	Less: Treasury share	71,364,020.00	71,364,020.00
其他综合收益	Other comprehensive income	3,706,443.79	3,817,428.85
专项储备	Special reserves		
盈余公积	Surplus reserve	297,080,875.00	297,080,875.00
一般风险准备	General risk reserves		
未分配利润	Retained earnings	6,664,060,427.40	6,568,056,149.20
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	10,842,590,528.90	10,742,506,022.92
少数股东权益	Non-controlling interests	360.25	404.72
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	10,842,590,889.15	10,742,506,427.64
负债和所有者权益(或股东权益)总计	Total liabilities owners' (or Shareholders') equity	11,719,954,413.58	11,715,023,471.80

公司负责人:	甘忠如	主管会计工作负责人:	孙程	会计机构负责人:	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并利润表

Consolidated income statement

2024年1—3月
Jan to Mar, 2024

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年第一季度 First quarter of 2024	2023年第一季度 First quarter of 2023
一、营业总收入	I. Total Revenue	560,334,209.70	557,999,537.96
其中:营业收入	Of which: Operating income	560,334,209.70	557,999,537.96
二、营业总成本	II. Total operating costs	541,954,966.18	528,077,591.01
其中:营业成本	Of which: Operating costs	152,249,465.95	150,830,624.26
税金及附加	Taxes and surcharges	6,264,933.61	6,061,051.09
销售费用	Selling expenses	227,086,625.00	224,729,850.74
管理费用	General and administrative expenses	43,299,233.12	46,800,804.48
研发费用	R&D expenses	133,120,155.74	119,936,250.47
财务费用	Financial expenses	-20,065,447.24	-20,280,990.03
加:其他收益	Add: Other income	6,339,484.78	5,295,268.14
投资收益(损失以“-”号填列)	Investment income or loss (loss is indicated with "-")	2,265,318.10	1,578,563.69
公允价值变动收益(损失以“-”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	85,501,251.91	17,706,102.62
信用减值损失(损失以“-”号填列)	Credit impairment losses (loss is indicated with "-")		5,183,449.30
资产减值损失(损失以“-”号填列)	Assets impairment losses (loss is indicated with "-")	49,622.31	
资产处置收益(损失以“-”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")	580,914.39	140,716.06
三、营业利润(亏损以“-”号填列)	III. Operating Profit (loss is indicated with "-")	113,115,835.01	59,826,046.76
加:营业外收入	Add: Non-operating income	519,781.04	72,251.09
减:营业外支出	Less: Non-operating expenses	75,272.07	2,207,715.29
四、利润总额(亏损总额以“-”号填列)	IV. Profit before tax (loss is indicated with "-")	113,560,343.98	57,690,582.56
减:所得税费用	Less: Income tax expense	17,556,110.25	8,467,364.65
五、净利润(净亏损以“-”号填列)	V. Net Profit (loss is indicated with "-")	96,004,233.73	49,223,217.91
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“-”号填列)	1. Net profit from continuing operations (loss is indicated with "-")	96,004,233.73	49,223,217.91

合并利润表 (续)
Consolidated income statement (Continued)

项目	Item	2024年第一季度 First quarter of 2024	2023年第一季度 First quarter of 2023
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润(净亏损以“-”号填列)	1. Net profit attributable to owners of the parent (net loss is indicated with "-")	96,004,278.20	49,223,261.29
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")	-44.47	-43.38
六、其他综合收益的税后净额	VI. Other comprehensive income net of tax	-110,985.06	-1,122,921.13
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	-110,985.06	-1,122,921.13
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-110,985.06	-1,122,921.13
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-110,985.06	-1,122,921.13
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	95,893,248.67	48,100,296.78
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	95,893,293.14	48,100,340.16
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-44.47	-43.38
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	0.16	0.09
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	0.16	0.09

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并现金流量表

Consolidated statement of cash flows

2024年1—3月
Jan to Mar, 2024

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年第一季度 First quarter of 2024	2023年第一季度 First quarter of 2023
一、经营活动产生的现金流量：			
I. Cash Flows from Operating Activities:			
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	648,170,407.38	521,288,359.88
收到的税费返还	Tax refunds received	35,184,163.91	19,057,286.19
收到其他与经营活动有关的现金	Cash received relating to other operating activities	5,344,312.42	6,532,168.71
经营活动现金流入小计	Sub-total of cash inflows from operating activities	688,698,883.71	546,877,814.78
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	167,310,878.41	141,805,607.71
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	206,967,260.27	187,822,557.25
支付的各项税费	Cash paid for taxes	28,622,858.18	29,372,680.15
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	204,509,532.12	204,137,090.44
经营活动现金流出小计	Sub-total of cash outflows from operating activities	607,410,528.98	563,137,935.55
经营活动产生的现金流量净额	Net cash flows from operating activities	81,288,354.73	-16,260,120.77
二、投资活动产生的现金流量：			
II. Cash Flows from Investing Activities:			
收回投资收到的现金	Cash received from recovery of investments	2,304,749,855.11	1,514,973,800.44
取得投资收益收到的现金	Cash receipts from investment income	22,772,877.41	11,921,797.48
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets	1,413,211.03	180,000.00
收到其他与投资活动有关的现金	Other cash received related to investing activities	2,021,519.97	11,614,356.00
投资活动现金流入小计	Sub-total of cash inflows from investing activities	2,330,957,463.52	1,538,689,953.92
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	137,137,802.25	139,562,957.82
投资支付的现金	Cash paid for investments	2,222,719,443.38	1,415,230,133.28
取得子公司及其他营业单位支付的现金净额	Net cash paid for acquisition of subsidiaries and other operating units		

合并现金流量表 (续)
Consolidated statement of cash flows (Continued)

项目	Item	2024年第一季度 First quarter of 2024	2023年第一季度 First quarter of 2023
支付其他与投资活动有关的现金	Cash paid relating to other investing activities		29,303,715.60
投资活动现金流出小计	Sub-total of cash outflows from investing activities	2,359,857,245.63	1,584,096,806.70
投资活动产生的现金流量净额	Net cash flows from investing activities	-28,899,782.11	-45,406,852.78
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
收到其他与筹资相关的现金	Cash received from other financing activities		
筹资活动现金流入小计	Subtotal of cash inflows from financing activities		
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	951,940.65	918,525.58
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	951,940.65	918,525.58
筹资活动产生的现金流量净额	Net cash flow from financing activities	-951,940.65	-918,525.58
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	44,446.57	-1,585,949.98
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	51,481,078.54	-64,171,449.11
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at beginning of period	286,438,980.59	397,328,882.98
六、期末现金及现金等价物余额	VI. Cash and cash equivalents at end of period	337,920,059.13	333,157,433.87

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会
The Board of Directors of Gan & Lee Pharmaceuticals.

2024年4月23日
April 23, 2024



SCIENCE & EXCELLENCE

甘李药业有限公司

地址：北京市通州区潮县镇南凤西一路8号

网址：<http://www.ganlee.com>

电话：+86 010-80593699

邮编：101109